论文部分内容阅读
目的:探讨酪酸梭菌活菌联合西药治疗老年人肠易激综合征(IBS)的疗效及对IL-18、IL-23和TNF-α的影响。方法:将88例IBS患者随机分为两组。观察组:46例IBS患者,接受酪酸梭菌活菌联合西药治疗。对照组:42例IBS患者,接受西药治疗。对比两组疗效及炎症水平。结果:观察组有效率优于对照组。观察组血清TNF-α水平明显较治疗前降低,也明显低于治疗后对照组血清TNF-α水平。观察组血清IL-18、IL-23水平明显较治疗前降低,也明显低于治疗后对照组血清IL-18、IL-23水平。结论:酪酸梭菌活菌联合西药治疗IBS,较单纯西药治疗优势明显,可抑制炎症反应,提高临床疗效。
Objective: To investigate the efficacy of Clostridium butyricum and western medicine in the treatment of irritable bowel syndrome (IBS) in elderly patients and its effect on IL-18, IL-23 and TNF-α. Methods: 88 IBS patients were randomly divided into two groups. Observation group: 46 patients with IBS were treated with Clostridium butyricum plus Western medicine. Control group: 42 patients with IBS received Western medicine. The curative effect and the level of inflammation were compared between the two groups. Results: The observation group was better than the control group. The level of TNF-α in the observation group was significantly lower than that before treatment, and also significantly lower than that of the control group after treatment. The levels of serum IL-18 and IL-23 in the observation group were significantly lower than those before treatment and also significantly lower than those in the control group after treatment. Conclusion: Clostridium butyricum combined with Western medicine in the treatment of IBS has obvious advantages over pure Western medicine in treating inflammatory bowel disease and improving clinical efficacy.